Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Head and neck cancers, Secondary cancers
Closed
Phase 1/2
This study is looking at new drug called alomfilimab (KY1044). It is looking at giving alomfilimab by itself and in combination with atezolizumab for advanced cancers of the head and neck.
It is open to people with a head and neck cancer that is a squamous cell type.
Recruitment start: 1 July 2022
Recruitment end: 8 August 2023
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Fiona Thistlethwaite
Kymab, a Sanofi Company
Last reviewed: 20 Aug 2023
CRUK internal database number: 18464
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
